Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

A Phase IIa, Open-Label, Multicenter Study of Single-Agent MOR00208, an Fc-Optimized Anti-CD19 Antibody, in Patients with Relapsed or Refractory B-Cell Non-Hodgkin’s Lymphoma

Kristie A. Blum, MD, Kami Maddocks, MD, Zsolt Nagy, MD, Pier Luigi Zinzani, MD PhD, Andre Goy, MD, Mariano Provencio, Tadeusz Robak, MD, Christian Buske, MD, Roman Pawel Korolkiewicz, MD, Mark Winderlich, Wojciech Jurczak, MD PhD

Blood (2014) 124 (21): 3089.

https://doi.org/10.1182/blood.V124.21.3089.3089

Published: 2014

Journal Articles

B-1239, a Novel Anti-BAFF-R Afucosylated Human Antibody, Promotes Potent Natural Killer Cell- Mediated Antibody Dependent Cellular Cytotoxicity In Chronic Lymphocytic Leukemia Cells In- Vitro and Depletion Of Circulating Leukemic CLL B Cells In-Vivo

Emily M. McWilliams, B.S., Carolyn Cheney, B.S, Jeffrey A. Jones, MD, MPH, Joseph M. M. Flynn, DO, MPH, Kami Maddocks, MD, Leslie A. Andritsos, MD, Heather Huet, PhD, Hermann Gram, Ph.D., Johan Baeck, MD, Natarajan Muthusamy, DVM, Ph.D, John C. Byrd, MD

Blood (2013) 122 (21): 4185.

https://doi.org/10.1182/blood.V122.21.4185.4185

Published: 2013

Journal Articles

Prognostic Significance Of Cytogenetic Complexity and Del(17p) At Diagnosis Of Chronic Lymphocytic Leukemia (CLL)

Nyla A. Heerema, PhD, Natarajan Muthusamy, DVM, Ph.D, Amy S. Ruppert, MAS, Leslie A Andritsos, MD, Michael R. Grever, MD, Jeffrey A. Jones, MD, MPH, Kami Maddocks, MD, John C. Byrd, MD

Blood (2013) 122 (21): 1321.

https://doi.org/10.1182/blood.V122.21.1321.1321

Published: 2013

Journal Articles

Dinaciclib (SCH 727965) Is a Novel Cyclin-Dependent Kinase (CDK) Inhibitor That Exhibits Activity In Patients With Relapsed Or Refractory Chronic Lymphocytic Leukemia (CLL)

Joseph M. M. Flynn, DO, MPH, Leslie A. Andritsos, MD, Jeffrey A. Jones, MD, MPH, Amy J. Johnson, PhD, Kami Maddocks, MD, Elizabeth Wiley, Karen Small, BSN, Eun Kyung Im, MD, Michael R. Grever, MD, Rajat Bannerji, MD, PhD, John C. Byrd, MD, Honghong Zhou, PhD

Blood (2013) 122 (21): 871.

https://doi.org/10.1182/blood.V122.21.871.871

Published: 2013

Journal Articles

Identification of Endoplasmic Reticulum Stress Inducing Agents by Antagonizing Autophagy: A New Potential Strategy for Identification of Anti-Cancer Therapeutics in B-Cell Malignancies.

Emilia Mahoney, MD, PhD, Sara L Cole, PhD, Kami Maddocks, MD, Joseph M. Flynn, DO, MPH, Jeffrey A. Jones, MD, MPH, Xiaoli Zhang, PhD, MS, John C. Byrd, MD, Amy J. Johnson, PhD

Blood (2012) 120 (21): 2473.

https://doi.org/10.1182/blood.V120.21.2473.2473

Published: 2012

Journal Articles

A Phase I Trial of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765), in Combination with Rituximab (R) and Bendamustine in Patients with Relapsed/Refractory Non-Hodgkin's Lymphoma (NHL)

Kristie A. Blum, MD, Beth Christian, MD, Joseph M. Flynn, DO, MPH, Samantha M. Jaglowski, MD, MPH, Jeffrey Alan Jones, MD, MPH, Kami Maddocks, MD, John C. Byrd, MD

Blood (2012) 120 (21): 1643.

https://doi.org/10.1182/blood.V120.21.1643.1643

Published: 2012

Journal Articles

The Hsp90 Inhibitor 17-DMAG Increases SOCS3 and Regulates Cytokine Production, Migration and Cell Death in Chronic Lymphocytic Leukemia

Erin K Hertlein, PhD, Timothy L. Chen, Rainer Claus, MD, Christoph Plass, PhD, Amy Lehman, David Jarjoura, PhD, Kami Maddocks, MD, Jeffrey A. Jones, MD, MPH, David M. Lucas, PhD, Amy J. Johnson, PhD, John C. Byrd, MD

Blood (2012) 120 (21): 1362.

https://doi.org/10.1182/blood.V120.21.1362.1362

Published: 2012

Journal Articles

Ibrutinib Is an Irreversible Molecular Inhibitor of Interleukin-2 Inducible Kinase: Expanding Therapeutic Potential and Modulating a Th1 Selective Pressure in CD4 T-Cells

Blood (2012) 120 (21): 775.

https://doi.org/10.1182/blood.V120.21.775.775

Published: 2012

Journal Articles

A Phase I Trial of the Intravenous (IV) Hsp90 Inhibitor 17-DMAG (alvespimycin) in Patients (pts) with Relapsed Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Kami Maddocks, MD, Erin K Hertlein, PhD, Joseph M. Flynn, DO, MPH, Leslie A Andritsos, MD, Amy J. Wagner, Timothy L. Chen, Mitch A. Phelps, PhD, Michael R. Grever, MD, Amy J. Johnson, PhD, John C. Byrd, MD, Jeffrey A. Jones, MD, MPH

Blood (2012) 120 (21): 1800.

https://doi.org/10.1182/blood.V120.21.1800.1800

Published: 2012

Journal Articles

Complete Response (CR) to Induction Therapy in Patients (pts) with Myc+ and Double Hit Non-Hodgkin's Lymphoma (NHL) Is Associated with Prolonged Progression-Free Survival (PFS).

Jonathon B. Cohen, MD, Susan Geyer, PhD, Gerard Lozanski, M.D., Weiqiang Zhao, MD PhD, Nyla A. Heerema, PhD, Jeffrey A. Jones, MD, MPH, Pierluigi Porcu, MD, Beth Christian, MD, Robert A. Baiocchi, M.D., Ph.D., Kami Maddocks, MD, Joseph M. Flynn, DO, MPH, Steven M. Devine, MD, Kristie A. Blum, MD

Blood (2012) 120 (21): 2693.

https://doi.org/10.1182/blood.V120.21.2693.2693

Published: 2012

Journal Articles

Treatment with Auranofin Induces Oxidative and Lethal Endoplasmic Reticulum (ER) Stress Exerting Single Agent Activity Against Primary CLL Cells

Rekha Rao, PhD, Kami Maddocks, MD, Amy J. Johnson, PhD, Lata Chauhan, PhD, Suman Kambhampati, MD, Siddhartha Ganguly, MD, Ruben Reyes, MD, Omar S. Aljitawi, MD, Kevin Schorno, MBA, Kendra Ford, MSN, RN, CCRC, Eileen Dickman, PhD, MBA, John C. Byrd, MD, Kapil N. Bhalla, MD

Blood (2011) 118 (21): 929.

https://doi.org/10.1182/blood.V118.21.929.929

Published: 2011

Journal Articles

Preliminary Results of a Phase I Study of Lenalidomide in Relapsed Chronic Lymphocytic Leukemia.

Kami Maddocks, MD, Rosa Lapalombella, PhD, Kristie A Blum, MD, William Blum, MD, Beth B. Fischer, Natarajan Muthusamy, PhD, Mollie E. Moran, Donna Holtzapfel, NP, John C. Byrd, Amy J. Johnson, PhD, Leslie Andritsos, MD,

Blood (2009) 114 (22): 3446.

https://doi.org/10.1182/blood.V114.22.3446.3446

Published: 2009

Journal Articles

Treatment Free Survival of Patients with MBL and Early CLL: Follow-up of 405 Patients at Mayo Clinic.

Tait Shanafelt, MD, Neil E. Kay, Kari Rabe, Timothy G. Call, Clive S. Zent, Kami Maddocks, MD, Diane F. Jelinek, Justin Boysen, Deborah Bowen, Susan Schwager, Gregory Jenkins, Susan L. Slager, PhD, Curtis A. Hanson

Blood (2008) 112 (11): 2063.

https://doi.org/10.1182/blood.V112.11.2063.2063

Published: 2008

NARROW

A Phase IIa, Open-Label, Multicenter Study of Single-Agent MOR00208, an Fc-Optimized Anti-CD19 Antibody, in Patients with Relapsed or Refractory B-Cell Non-Hodgkin’s Lymphoma

B-1239, a Novel Anti-BAFF-R Afucosylated Human Antibody, Promotes Potent Natural Killer Cell- Mediated Antibody Dependent Cellular Cytotoxicity In Chronic Lymphocytic Leukemia Cells In- Vitro and Depletion Of Circulating Leukemic CLL B Cells In-Vivo

Prognostic Significance Of Cytogenetic Complexity and Del(17p) At Diagnosis Of Chronic Lymphocytic Leukemia (CLL)

Dinaciclib (SCH 727965) Is a Novel Cyclin-Dependent Kinase (CDK) Inhibitor That Exhibits Activity In Patients With Relapsed Or Refractory Chronic Lymphocytic Leukemia (CLL)

Identification of Endoplasmic Reticulum Stress Inducing Agents by Antagonizing Autophagy: A New Potential Strategy for Identification of Anti-Cancer Therapeutics in B-Cell Malignancies.

A Phase I Trial of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765), in Combination with Rituximab (R) and Bendamustine in Patients with Relapsed/Refractory Non-Hodgkin's Lymphoma (NHL)

The Hsp90 Inhibitor 17-DMAG Increases SOCS3 and Regulates Cytokine Production, Migration and Cell Death in Chronic Lymphocytic Leukemia

Ibrutinib Is an Irreversible Molecular Inhibitor of Interleukin-2 Inducible Kinase: Expanding Therapeutic Potential and Modulating a Th1 Selective Pressure in CD4 T-Cells

A Phase I Trial of the Intravenous (IV) Hsp90 Inhibitor 17-DMAG (alvespimycin) in Patients (pts) with Relapsed Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Complete Response (CR) to Induction Therapy in Patients (pts) with Myc+ and Double Hit Non-Hodgkin's Lymphoma (NHL) Is Associated with Prolonged Progression-Free Survival (PFS).

Treatment with Auranofin Induces Oxidative and Lethal Endoplasmic Reticulum (ER) Stress Exerting Single Agent Activity Against Primary CLL Cells

Preliminary Results of a Phase I Study of Lenalidomide in Relapsed Chronic Lymphocytic Leukemia.

Treatment Free Survival of Patients with MBL and Early CLL: Follow-up of 405 Patients at Mayo Clinic.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only